JP2021518428A5 - - Google Patents
Info
- Publication number
- JP2021518428A5 JP2021518428A5 JP2020573073A JP2020573073A JP2021518428A5 JP 2021518428 A5 JP2021518428 A5 JP 2021518428A5 JP 2020573073 A JP2020573073 A JP 2020573073A JP 2020573073 A JP2020573073 A JP 2020573073A JP 2021518428 A5 JP2021518428 A5 JP 2021518428A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cells
- patent document
- tumor
- col
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643378P | 2018-03-15 | 2018-03-15 | |
| US62/643,378 | 2018-03-15 | ||
| US201862651916P | 2018-04-03 | 2018-04-03 | |
| US62/651,916 | 2018-04-03 | ||
| PCT/US2019/022245 WO2019178342A1 (en) | 2018-03-15 | 2019-03-14 | Programmable immunocyte receptor complex system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518428A JP2021518428A (ja) | 2021-08-02 |
| JP2021518428A5 true JP2021518428A5 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| JP7462578B2 JP7462578B2 (ja) | 2024-04-05 |
Family
ID=67905164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573073A Active JP7462578B2 (ja) | 2018-03-15 | 2019-03-14 | プログラム可能な免疫細胞受容体複合体システム |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20190284255A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3765093A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7462578B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102867256B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955184A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019178342A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11117936B2 (en) * | 2017-11-10 | 2021-09-14 | University of Pittsburg—Of the Commonwealth System of Higher Education | Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR) |
| WO2019178342A1 (en) | 2018-03-15 | 2019-09-19 | Fundamental Solutions Corporation | Programmable immunocyte receptor complex system |
| AU2020325225A1 (en) * | 2019-08-05 | 2022-03-24 | Cartherics Pty. Ltd. | Immune cells expressing modified cell receptors and methods of making |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874239A (en) | 1993-07-30 | 1999-02-23 | Affymax Technologies N.V. | Biotinylation of proteins |
| GB9721075D0 (en) * | 1997-10-03 | 1997-12-03 | Cancer Res Campaign Tech | Materials and methods relating to the stimulation of cells |
| FI20021518A0 (fi) * | 2002-08-23 | 2002-08-23 | Jyvaeskylaen Yliopisto | Avidiinin lämpökestävyyden lisääminen |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| WO2014055442A2 (en) * | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| NZ759969A (en) * | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| PL3212225T3 (pl) * | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytów t |
| US9752199B2 (en) | 2015-03-31 | 2017-09-05 | Fundamental Solutions Corporation | Biosensor system for the rapid detection of analytes |
| IL254687B2 (en) * | 2015-03-31 | 2024-01-01 | Fundamental Solutions Corp | Biosensor system for the rapid detection of analytes |
| US20180161369A1 (en) * | 2015-05-29 | 2018-06-14 | Fred Hutchinson Cancer Research Center | Compositions for cellular immunotherapy |
| US12121539B2 (en) * | 2015-09-11 | 2024-10-22 | Biosceptre (Aust) Pty Ltd | Chimeric antigen receptors and uses thereof |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2019178342A1 (en) | 2018-03-15 | 2019-09-19 | Fundamental Solutions Corporation | Programmable immunocyte receptor complex system |
-
2019
- 2019-03-14 WO PCT/US2019/022245 patent/WO2019178342A1/en not_active Ceased
- 2019-03-14 US US16/353,337 patent/US20190284255A1/en not_active Abandoned
- 2019-03-14 EP EP19767510.1A patent/EP3765093A4/en active Pending
- 2019-03-14 JP JP2020573073A patent/JP7462578B2/ja active Active
- 2019-03-14 KR KR1020207029506A patent/KR102867256B1/ko active Active
- 2019-03-14 CN CN201980032485.3A patent/CN112955184A/zh active Pending
- 2019-03-14 KR KR1020257032463A patent/KR20250151559A/ko active Pending
-
2020
- 2020-06-10 US US16/897,885 patent/US12234273B2/en active Active
-
2025
- 2025-02-14 US US19/054,060 patent/US20250197472A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pol et al. | First oncolytic virus approved for melanoma immunotherapy | |
| Huang et al. | Application of oncolytic virus in tumor therapy | |
| Bridle et al. | Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines | |
| Perera et al. | HCMV antivirals and strategies to target the latent reservoir | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| Taguchi et al. | Current status of clinical trials assessing oncolytic virus therapy for urological cancers | |
| JP2022163182A5 (cg-RX-API-DMAC7.html) | ||
| JP2022519595A5 (cg-RX-API-DMAC7.html) | ||
| Francis et al. | Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer | |
| JP2014532649A5 (cg-RX-API-DMAC7.html) | ||
| Shen et al. | VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes | |
| Singh et al. | Latency reversal 2.0: giving the immune system a seat at the table | |
| Stoker et al. | Epstein–Barr virus-targeted therapy in nasopharyngeal carcinoma | |
| GB2286593A (en) | Virus with modified binding moiety specific for the target cells | |
| JP2019523008A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520997A5 (cg-RX-API-DMAC7.html) | ||
| Horng et al. | HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice | |
| Wang et al. | CBX4 suppresses CD8+ T cell antitumor immunity by reprogramming glycolytic metabolism | |
| Bertzbach et al. | Viral factors involved in Marek’s disease virus (MDV) pathogenesis | |
| Yang et al. | Progress in gene therapy using oncolytic vaccinia virus as vectors | |
| Jazowiecka-Rakus et al. | Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma | |
| Alemany et al. | Oncolytic viruses from the perspective of the immune system | |
| Zhang et al. | Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model | |
| JP2019517262A5 (cg-RX-API-DMAC7.html) | ||
| Holay et al. | Sharpening the edge for precision cancer immunotherapy: targeting tumor antigens through oncolytic vaccines |